Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pergolide
Drug ID BADD_D01735
Description Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
Indications and Usage Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.
Marketing Status approved; investigational; vet_approved; withdrawn
ATC Code N04BC02
DrugBank ID DB01186
KEGG ID D08339
MeSH ID D010479
PubChem ID 47811
TTD Drug ID D04JCN
NDC Product Code Not Available
UNII 24MJ822NZ9
Synonyms Pergolide | Pharken | Permax | Celance | Parkotil | LY-127809 | LY127809 | LY-127,809 | LY127,809 | Pergolide Mesylate | Mesylate, Pergolide
Chemical Information
Molecular Formula C19H26N2S
CAS Registry Number 66104-22-1
SMILES CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyrexia08.05.02.003--
Pyuria20.08.02.016; 11.01.08.043--Not Available
Rash23.03.13.001--Not Available
Rash pustular23.03.10.003; 11.01.12.002--
Renal failure20.01.03.005--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Retinal detachment12.01.04.004; 06.09.03.003--
Retinal vascular disorder24.03.07.002; 06.10.01.002--
Rhinitis22.07.03.006; 11.01.13.004--
Salivary gland enlargement07.06.03.002--Not Available
Salpingitis11.01.10.001; 21.14.03.001--Not Available
Seborrhoea23.02.07.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Shock24.06.02.002--Not Available
Sialoadenitis11.01.04.002; 07.06.04.002--
Sinusitis22.07.03.007; 11.01.13.005--
Skin cancer23.08.02.002; 16.03.02.002--Not Available
Skin discolouration23.03.03.005--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Splenomegaly01.09.02.001--Not Available
Stupor19.02.05.004; 17.02.04.007--Not Available
Surgery25.01.02.003--Not Available
Syncope17.02.04.008; 02.11.04.015; 24.06.02.012--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachycardia02.03.02.007--Not Available
Tenosynovitis15.07.01.004--Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages